Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
CompletedNCT00224510
Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Depression for manic episodes in bipolarity
This study is completed in the Netherlands and in Spain. It is testing lamotrigine for manic episodes in bipolarity.
Bipolarity, DepressionDrugOver 18 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
Check the study details
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: August 2002
- Recruitment status
- Completed
- Enrollment listed in the registry
- 120
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Netherlands, Spain
- Age range
- Over 18 Years
- Official registry ID
- NCT00224510
- Official title
- A Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Bipolar Depression, Followed by Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients With Bipolar Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
View official study record (opens in a new tab)The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Netherlands · 25 sites
- GSK Investigational SiteAlkmaarSite status: Not listed — confirm with the team
- GSK Investigational SiteAlmeloSite status: Not listed — confirm with the team
- GSK Investigational SiteAmersfoortSite status: Not listed — confirm with the team
- GSK Investigational SiteAmsterdamSite status: Not listed — confirm with the team
- GSK Investigational SiteAmsterdamSite status: Not listed — confirm with the team
- GSK Investigational SiteBennebroekSite status: Not listed — confirm with the team
- GSK Investigational SiteBlaricumSite status: Not listed — confirm with the team
- GSK Investigational SiteDelftSite status: Not listed — confirm with the team
- GSK Investigational SiteDordrechtSite status: Not listed — confirm with the team
- GSK Investigational SiteEindhovenSite status: Not listed — confirm with the team
- GSK Investigational SiteEnschedeSite status: Not listed — confirm with the team
- GSK Investigational SiteFlushingSite status: Not listed — confirm with the team
- GSK Investigational SiteGoudaSite status: Not listed — confirm with the team
- GSK Investigational SiteGroningenSite status: Not listed — confirm with the team
- GSK Investigational SiteHoornSite status: Not listed — confirm with the team
- GSK Investigational SiteLeidenSite status: Not listed — confirm with the team
- GSK Investigational SiteNijmegenSite status: Not listed — confirm with the team
- GSK Investigational SiteRaalteSite status: Not listed — confirm with the team
- GSK Investigational SiteRetranchementSite status: Not listed — confirm with the team
- GSK Investigational SiteRosmalenSite status: Not listed — confirm with the team
- GSK Investigational SiteThe HagueSite status: Not listed — confirm with the team
- GSK Investigational SiteTilburgSite status: Not listed — confirm with the team
- GSK Investigational SiteUtrechtSite status: Not listed — confirm with the team
- GSK Investigational SiteWeertSite status: Not listed — confirm with the team
- GSK Investigational SiteZwolleSite status: Not listed — confirm with the team
Spain · 6 sites
- GSK Investigational SiteAlavaSite status: Not listed — confirm with the team
- GSK Investigational SiteBarcelonaSite status: Not listed — confirm with the team
- GSK Investigational SiteBarcelonaSite status: Not listed — confirm with the team
- GSK Investigational SiteBarcelonaSite status: Not listed — confirm with the team
- GSK Investigational SiteMadridSite status: Not listed — confirm with the team
- GSK Investigational SiteValenciaSite status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00224510. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving lamotrigine. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with bipolarity; age range: Over 18 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by GlaxoSmithKline, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2004-003826-92
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedNCT03039192
Intranasal Esketamine for depression
This study is completed in the United States, in Bulgaria, in Estonia, .... It is testing intranasal Esketamine for depression.
CompletedNCT03097133
Intranasal Esketamine for depression
This study is completed in the United States, in France, in Canada, .... It is testing intranasal Esketamine for depression.